The oncogene HER2 is overexpressed in around 20% of all cases while the remaining 20% are negative for the expression of ER, PR, and HER2, also known as triple-negative breast cancer (TNBC) (5, 6). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.